Overview

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2027-09-30

Target enrollment:

Participant gender:

Summary

To find the recommended dose of MRTX849 that can be given in combination with cetuximab and irinotecan to patients with colorectal cancer that have a mutation (genetic change) called KRAS G12C.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Mirati Therapeutics

Treatments:

Adagrasib
Cetuximab
Irinotecan